Baseline clinical characteristics, therapy, response, and progression status of the PCNSL population (n = 78)
| . | Median (range) . |
|---|---|
| Age at diagnosis (y) | 64 (22-87) |
| KPS | 70 (30-90) |
| Patients (%) | |
| IELSG risk group | |
| Low risk (0-1) | 22 (28.2%) |
| Intermediate risk (2-3) | 49 (62.8%) |
| High risk (4-5) | 6 (7.7%) |
| NA | 1 (1.3%) |
| Race and ethnicity | |
| White | 40 (51.3%) |
| Asian | 25 (32.1%) |
| Hispanic | 10 (12.8%) |
| African American | 2 (2.5%) |
| Native American | 1 (1.3%) |
| Cell of origin | |
| ABC-DLBCL | 60 (76.9%) |
| GCB-DLBCL | 13 (16.7%) |
| NA | 5 (6.4%) |
| IOL | 9 (11.5%) |
| CSF involvement | |
| Positive or suspicious | 6 (7.7%) |
| Negative | 44 (56.4%) |
| Unknown | 28 (35.9%) |
| Tumor focality | |
| Unifocal | 42 (53.8%) |
| Multifocal | 36 (46.2%) |
| Induction therapy | |
| MTR | 76 (97.4%) |
| M-R | 2 (2.6%) |
| Response to induction | |
| CR | 51 (65.4%) |
| PR | 10 (12.8%) |
| PD | 17 (21.8%) |
| Postinduction treatment | |
| Dose-intensive consolidation | 44 (56.4%) |
| Maintenance immunotherapy | 8 (10.3%) |
| No additional therapy | 9 (11.5%) |
| Progression status | |
| During first 6 mo | 17 (21.8%) |
| After 6 mo | 18 (23.1%) |
| Not progressed | 43 (55.1%) |
| . | Median (range) . |
|---|---|
| Age at diagnosis (y) | 64 (22-87) |
| KPS | 70 (30-90) |
| Patients (%) | |
| IELSG risk group | |
| Low risk (0-1) | 22 (28.2%) |
| Intermediate risk (2-3) | 49 (62.8%) |
| High risk (4-5) | 6 (7.7%) |
| NA | 1 (1.3%) |
| Race and ethnicity | |
| White | 40 (51.3%) |
| Asian | 25 (32.1%) |
| Hispanic | 10 (12.8%) |
| African American | 2 (2.5%) |
| Native American | 1 (1.3%) |
| Cell of origin | |
| ABC-DLBCL | 60 (76.9%) |
| GCB-DLBCL | 13 (16.7%) |
| NA | 5 (6.4%) |
| IOL | 9 (11.5%) |
| CSF involvement | |
| Positive or suspicious | 6 (7.7%) |
| Negative | 44 (56.4%) |
| Unknown | 28 (35.9%) |
| Tumor focality | |
| Unifocal | 42 (53.8%) |
| Multifocal | 36 (46.2%) |
| Induction therapy | |
| MTR | 76 (97.4%) |
| M-R | 2 (2.6%) |
| Response to induction | |
| CR | 51 (65.4%) |
| PR | 10 (12.8%) |
| PD | 17 (21.8%) |
| Postinduction treatment | |
| Dose-intensive consolidation | 44 (56.4%) |
| Maintenance immunotherapy | 8 (10.3%) |
| No additional therapy | 9 (11.5%) |
| Progression status | |
| During first 6 mo | 17 (21.8%) |
| After 6 mo | 18 (23.1%) |
| Not progressed | 43 (55.1%) |
Each of the patients with intraocular and/or CSF/leptomeningeal dissemination also had evidence of brain parenchymal lymphoma at presentation.
ABC, activated B cell; CR, complete response; CSF, cerebrospinal fluid; GCB, germinal center B cell; IOL, intraocular lymphoma; KPS, Karnofsky performance status; M-R, high-dose methotrexate plus rituximab; NA, not available; PD, progressive disease; PR, partial response.